Catherine Dubos‐Arvis

Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018

Florian Guisier, Catherine Dubos‐Arvis, F. Viñas et al. · Journal of Thoracic Oncology · 2020 · 296 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

Julien Mazières, Claire Cropet, Laure Montané et al. · Annals of Oncology · 2020 · 189 citations

Pharmacy, Molecular Genetics, Pharmacotherapy +15

Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients

Charline Lasnon, Cédric Desmonts, Elske Quak et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 125 citations · Full text

Medicine, Nuclear Medicine, Oncology +16

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez, Julien Mazières, A. Lavolé et al. · Journal for ImmunoTherapy of Cancer · 2022 · 114 citations · Full text

Medicine, Oncology, Chemotherapy +14